Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Merck’s once-daily IDVYNSO™ (doravirine/islatravir) receives FDA approval

Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) approved IDVYNSO™, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1...

Orthogon Therapeutics Raises an Additional $11M Financing for Its BK Virus Antiviral Drug Program

Orthogon Therapeutics announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first-in-class drug against BK polyomavirus. BK virus...

Approval and Launch of Nintedanib Capsules

Dexcel Pharma USA is pleased to announce that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules, 100 mg and 150 mg, the generic equivalent of...

Epia Neuro Launches Intent-Driven Neural Technology to Restore Function After Stroke and Address Cognitive Decline

Epia Neuro, a brain computer interface company developing intent-driven systems to restore independence for people living with neurological conditions, announced its official launch. The company is advancing a proprietary neural interface platform...

Fast-Acting Covalent Protein Drugs Developed from a New High-Throughput Platform

A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory reported in Science a high-throughput platform for engineering fast-acting covalent protein therapeutics. Their work, titled "A...

Thermo Fisher Scientific Unveils Integrated Platform to Enhance Biologics Development

Thermo Fisher Scientific the world leader in serving science, announced a next-generation, integrated cell line development platform that enables biologics developers to accelerate time to clinic while maintaining regulatory confidence and...

Orca Bio Announces FDA Extension of BLA Review for Orca-T in the Treatment of Hematologic Malignancies.

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline of its Biologics License...

CellCentric Launches DOMMINO-1, a Phase 2 Trial of Inobrodib Combined with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

CellCentric, a clinical-stage biotechnology company developing inobrodib as a first-in-a-class, oral p300/CBP inhibitor for the treatment of multiple myeloma, announced the initiation of DOMMINO-1, a pivotal Phase 2 clinical trial evaluating...

Constance Sabbagh Appointed as General Manager as Avanzanite Expands French Operations

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh...

Emerging From Stealth, Oryon Cell Therapies Targets Autologous Neuron Replacement for Parkinson’s Disease and Neurodegenerative Disorders

Oryon Cell Therapies a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders, announced it has emerged from stealth and has closed a new $21...

Convergent Therapeutics Appoints Michael Rossi to Board

Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of prostate cancer, announced the appointment of Michael Rossi to its Board of Directors. Mr. Rossi...

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.

Johnson & Johnson a worldwide leader in multiple myeloma therapies, announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of...

Cognito Therapeutics Announces $105 Million Oversubscribed Series C Financing to Advance Spectris™ in Alzheimer’s Disease.

-Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, today announced the final close of its oversubscribed $105 million Series C funding. The round...

Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

Eton Pharmaceuticals, Inc an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced it has in-licensed U.S. commercialization rights to HEMANGEOL® oral solution from Pierre Fabre...

30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

Merck known as MSD outside of the United States and Canada, and Eisai today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG® (belzutifan). Merck’s first-in-class oral...

Rebeca Villarreal-Barragan, MBA, Appointed Head of Clinical Operations at 3T Biosciences

3T Biosciences, an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, announced the appointment of Rebeca Villarreal-Barragan, MBA, as head of clinical operations. In this role, Ms....

Neurizon Begins Dosing of NUZ-001 in HEALEY ALS Platform Trial

Neurizon® Therapeutics Limited a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the first participant has been dosed in Regimen I of the HEALEY ALS...

Ron Mayron Becomes Chairman of the Board of Matricelf Ltd

Matricelf Ltd. a biotechnology company developing autologous engineered tissue therapies, today announced the appointment of Mr. Ron Mayron as Active Chairman of the Board of Directors. Mr. Mayron's appointment follows shareholder approval and...

Unique Mouse Model Enables genOway to Transform Prediction of Antibody Therapies in Humans

Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows that genOway's genO-hFcγR mouse model enables more...

ARUP Laboratories Establishes Innovation Central Laboratory to Accelerate Diagnostic Innovation for Biotechnology and Pharmaceutical Partners

ARUP Laboratories, a leader in diagnostic medicine and the largest nonprofit reference laboratory in the U.S., announced the launch of a new Innovation Central Laboratory to facilitate collaboration with pharmaceutical, biotechnology, and other...